When anxiety interferes with daily life, mindfulness‑based stress reduction works just as well as common anti‑anxiety drugs
276 adults diagnosed with anxiety disorder were randomly split into two groups. One group attended an eight‑week mindfulness‑based stress reduction course, while the other took escitalopram. At the end, symptom improvement was almost identical in both groups. The difference showed up in side effects: almost 80 % of the medication group experienced at least one adverse reaction, and ten people dropped out because of this. In the course group, about 15 % reported side effects, but no one left the program. The program used a standardized eight‑week curriculum — it isn’t the same as any random meditation app you might download.
Taking a course costs a bit of money. The program lasts ei…
This was a non‑inferiority randomized controlled trial conducted at three academic medical centers in the Unit…
Taking a course costs a bit of money. The program lasts eight weeks, with one class per week plus daily home practice. The real challenge is keeping up with that daily practice for the whole eight weeks.
This was a non‑inferiority randomized controlled trial conducted at three academic medical centers in the United States, designed to see whether the course performed as well as medication. 276 participants were assigned 1:1 to either an eight‑week mindfulness‑based stress reduction program or escitalopram at a flexible dose of 10–20 mg. 208 people completed the whole study. Using a clinician‑rated scale of anxiety severity, the mindfulness group showed a reduction of 1.35 points versus 1.43 points for the drug group. The difference between the two groups was −0.07 (95 % CI −0.38 to 0.23; P = 0.65), meaning the gap is statistically indistinguishable from zero. This value stayed above the pre‑set non‑inferiority threshold of −0.495. Side‑effect rates differed markedly: 78.6 % of the medication group experienced at least one trial‑related adverse event, leading to ten withdrawals, while only 15.4 % of the course group reported any side effects and no one dropped out.
Hoge EA, Bui E, Mete M, Dutton MA, Baker AW, Simon NM (2023). Mindfulness-based stress reduction vs escitalopram for the treatment of adults with anxiety disorders: a randomized clinical trial. JAMA Psychiatry, 80(1), 13-21. https://doi.org/10.1001/jamapsychiatry.2022.3679
Open source linkThe trial employed a standardized eight‑week mindfulness‑based stress reduction curriculum (MBSR), not a generic meditation app; the two cannot be equated. This recommendation applies to individuals who already meet diagnostic criteria for anxiety disorder; they should still consult a physician. Its practical value lies in offering a treatment option with comparable evidence strength for those who hesitate to take medication because of potential side effects.